euro-biotechnology-2016_keynote

2 / 7

Volume 6, Issue 7(Suppl) J Biotechnol Biomater
ISSN: 2155-952X JBTBM, an open access journal
Page 18
Euro Biotechnology 2016
November 07-09, 2016
conferenceseries.com
November 07-09, 2016 Alicante, Spain
12th Euro Biotechnology Congress
Stefan Selbert, J Biotechnol Biomater 2016, 6:7(Suppl)
State-of-the-art technologies for the generation of animal models of human disease
Animal models play a critical role in the exploration and characterization of disease pathophysiology, target identification
and in the in vivo evaluation of novel therapeutic agents and treatments. The “better” the animal model, the higher
the chances that clinical trials will be successful and drugs will enter the market at lower costs, in shorter time. Genome
engineering technologies have soared in recent years: Chemical mutagenesis, RNA interference, gene targeting in ES-cells,
humanized genes and most recently nucleases, such as ZFNs, TALENs and CRISPR/Cas9. New technologies provide new
avenues not only to mimic multi factor based disease such as cancer but also to extend model generation on higher species and
even human or patient derived cells and tissue. New inducible switches are underway which will allow altering gene expression
of not just one but multiple genes and even entire signal transduction pathways within the same cell and tissue, e.g., during
disease progression at will in a temporospatial control way. Technologies presented will be of tremendous value for future
generations of cellular or animal models and when carefully selected, designed and conducted will play an important part of
any translational drug development strategy.
Biography
Stefan Selbert has achieved his PhD at the Max-Planck-Institute of Biochemistry in Martinsried and holds a certificate in Business Administration. He also functions
as an Evaluator in Brussels for EU-FP7-PEOPLE and EUREKA Eurostar programs.
Stefan Selbert
PolyGene Transgenetics, Switzerland